We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Unlocking New Cures: How Functional Genomic Screening Revolutionizes Drug Discovery

In this exclusive Teach Me in 10 episode, Dr. James Goldmeyer, Associate Director at Revvity, explores the transformative impact of functional genomic screening in drug discovery. Revvity, a leading organization, offers comprehensive solutions across research, development, diagnosis, and treatment. Dr. Goldmeyer discusses how this cutting-edge technique, involving CRISPR-based technologies and RNA interference, enhances precision in developing personalized treatments and bridges the gap left by traditional methods.

The discussion highlights functional genomic screening's pivotal role in drug discovery, aiding in target identification, drug response mechanisms, and in vivo tumor biology. It also addresses potential disadvantages, providing a well-rounded understanding.

Emphasizing Revvity's focus on gene modification and its potential applications in various diseases, the interview reveals how functional genomic screening accelerates drug discovery and supports innovative cell-based therapies.

Further Resources:

Brought to you by